COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)					1 Months Ended							3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 01, 2024	Dec. 20, 2023	Aug. 01, 2023	Aug. 27, 2018	Oct. 31, 2024	Aug. 31, 2023	Jul. 31, 2022	Apr. 30, 2022	May 31, 2020	Oct. 31, 2019	Jul. 31, 2019	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2025	Apr. 04, 2022	Apr. 30, 2020
Loss Contingencies [Line Items]
Payment in cash													$ 3,089,645
Options to acquire shares
Cost of Sales [Member]
Loss Contingencies [Line Items]
Payment for additional royalties													9,209		$ 1,060,035
Sub License Agreement [Member]
Loss Contingencies [Line Items]
License agreement and royalties description				In August 2018, the Company entered an exclusive, world-wide sublicense agreement with CGI Cellerate RX to distribute certain hydrolyzed collagen products, including CellerateRX Surgical, into the surgical and wound care markets. Pursuant to the Sublicense Agreement, the Company paid royalties of 3-5% of annual collected net sales of these products. As amended in January 2021, the term of the sublicense was extended through May 2050, with automatic successive year-to-year renewal terms thereafter so long as the Company’s Net Sales (as defined in the Sublicense Agreement) each year are equal to or in excess of $1,000,000. If the Company’s Net Sales fall below $1,000,000 for any year after the expiration date, CGI Cellerate RX has the right to terminate the Sublicense Agreement upon written notice.
BIAKOS License Agreement [Member]
Loss Contingencies [Line Items]
Payment for additional royalties												$ 36,602	$ 32,499	113,907	$ 97,499
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty percentage											2.00%
Annual royalty														$ 146,410
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty percentage											4.00%
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member] | Forecast [Member]
Loss Contingencies [Line Items]
Annual royalty																$ 150,000
BIAKOS Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Payment for additional royalties											$ 1,000,000
ABF License Agreement [Member]
Loss Contingencies [Line Items]
Increase in royalty annual percentage										10.00%
ABF License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Payment for additional royalties										$ 50,000
Royalty percentage										2.00%
ABF License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Payment for additional royalties										$ 75,000
Royalty percentage										4.00%
ABF License Agreement [Member] | Maximum [Member] | Product and Service, Other [Member]
Loss Contingencies [Line Items]
Payment for additional royalties										$ 500,000
Debrider License Agreement [Member]
Loss Contingencies [Line Items]
Increase in royalty annual percentage									10.00%
Payment of cash									$ 1,000,000
Debrider License Agreement [Member] | Rochal [Member]
Loss Contingencies [Line Items]
Cash									$ 500,000
Debrider License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty percentage									2.00%
Annual royalty									$ 100,000
Debrider License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty percentage									4.00%
Annual royalty									$ 150,000
Payment for additional royalties									$ 1,000,000
Precision Healing Merger Agreement [Member]
Loss Contingencies [Line Items]
Cash consideration								$ 125,966
Payment in cash								$ 600,000
Share price								$ 27.13									$ 30.75	$ 27.13
Options to acquire shares								144,191
Weighted exercise price								$ 10.71
Contingent consideration payments receivable								$ 10,000,000.0
Precision Healing Merger Agreement [Member] | Warrant [Member]
Loss Contingencies [Line Items]
Warrants to purchase shares								4,424
Exercise price								$ 7.32
Expiration date								Apr. 22, 2031
Precision Healing Merger Agreement [Member] | Warrant One [Member]
Loss Contingencies [Line Items]
Warrants to purchase shares								12,301
Exercise price								$ 12.05
Expiration date								Aug. 10, 2030
Precision Healing Merger Agreement [Member] | Accredited Investors [Member]
Loss Contingencies [Line Items]
Issuance of shares								165,738
Scendia Purchase Agreement [Member]
Loss Contingencies [Line Items]
Cash							$ 1,600,000
Acquisition consideration transferred							$ 7,600,000
Issuance of common stock for purchase of assets							291,686
Number of shares withheld							94,798
Earnout consideration							$ 10,000,000.0
Number of shares issuable							486,145
Earnout payment						$ 693,000
Assets purchase price							$ 7,600,000
Scendia Purchase Agreement [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Earnout payment					$ 1,100,000
Applied Asset Purchase Agreement [Member]
Loss Contingencies [Line Items]
Cash consideration			$ 16,792,037
Contingent consideration payments receivable			$ 893,000
Issuance of common stock for purchase of assets			73,809
Assets purchase price			$ 15,250,000
Purchase agreement description			As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain products the Owner develops or co-develops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.
Services Agreement [Member]
Loss Contingencies [Line Items]
Purchase agreement description			As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain products the Owner develops or codevelops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.
License Agreement [Member]
Loss Contingencies [Line Items]
Payment for additional royalties	$ 50,000
Outstanding units percentage		10.00%
License Agreement [Member] | Royalty Agreement Terms [Member]
Loss Contingencies [Line Items]
Payment for additional royalties	$ 100,000
License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty expense percentage		1.50%
License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty expense percentage		3.00%